Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 3/20 | 0.75 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.75 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.75 |
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.67 |
| ▸ | STAT6 | P42226 | 1/20 | 0.67 |
| ▸ | GMNN | O75496 | 1/20 | 0.67 |
| ▸ | BLM | P54132 | 1/20 | 0.67 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.67 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.66 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.64 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.64 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL640190 | 1.00 | ADORA1 (0.75) | ADORA1ADORA3ADORA2ATSHRNFKB1 | |
| SCHEMBL17825998 | 1.00 | ADORA1 (0.75) | ADORA1ADORA3ADORA2ATSHRNFKB1 | |
| SCHEMBL640189 | 1.00 | ADORA1 (0.75) | ADORA1ADORA3ADORA2ATSHRNFKB1 | |
| SCHEMBL30411984 | 0.99 | ADORA1 (0.74) | ADORA1ADORA3ADORA2ATSHRNFKB1 | |
| SCHEMBL640010 | 0.93 | ADORA3 (0.83) | ADORA1ADORA3ADORA2ATSHRNFKB1 | |
| SCHEMBL640011 | 0.93 | ADORA3 (0.83) | ADORA1ADORA3ADORA2ATSHRNFKB1 | |
| SCHEMBL19583146 | 0.93 | ADORA3 (0.83) | ADORA1ADORA3ADORA2ATSHRNFKB1 | |
| SCHEMBL25173766 | 0.92 | ADORA3 (0.82) | ADORA1ADORA3ADORA2ATSHRNFKB1 | |
| SCHEMBL639137 | 0.92 | PAX8 (0.73) | ADORA1ADORA3ADORA2ATSHRNFKB1 | |
| SCHEMBL639392 | 0.92 | ADORA3 (0.75) | ADORA1ADORA3ADORA2ATSHRNFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3229771-B1 | 6-ARYL-9-GLYCOSYLPURINES AND USE THEREOF | UNIV PALACKEHO (CZ) | 2024-04-03 | — | — | EP | claimed |
| EP-3229772-B1 | 6-ARYL-9-GLYCOSYLPURINES AND USE THEREOF | UNIV PALACKEHO (CZ) | 2020-04-29 | — | — | EP | claimed |
| US-10550144-B2 | 6-aryl-9-glycosylpurines and use thereof | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2020-02-04 | — | — | US | claimed |
| US-10100077-B2 | 6-aryl-9-glycosylpurines and use thereof | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2018-10-16 | — | — | US | claimed |
| US-20170334943-A1 | 6-ARYL-9-GLYCOSYLPURINES AND USE THEREOF | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2017-11-23 | — | — | US | claimed |
| US-20170326168-A1 | 6-ARYL-9-GLYCOSYLPURINES AND USE THEREOF | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2017-11-16 | — | — | US | claimed |
| EP-3229771-B1 | 6-ARYL-9-GLYCOSYLPURINES AND USE THEREOF | UNIV PALACKEHO (CZ) | 2024-04-03 | — | — | EP | disclosed |
| EP-3229772-B1 | 6-ARYL-9-GLYCOSYLPURINES AND USE THEREOF | UNIV PALACKEHO (CZ) | 2020-04-29 | — | — | EP | disclosed |
| US-10550144-B2 | 6-aryl-9-glycosylpurines and use thereof | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2020-02-04 | — | — | US | disclosed |
| US-10100077-B2 | 6-aryl-9-glycosylpurines and use thereof | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2018-10-16 | — | — | US | disclosed |
| US-20170334943-A1 | 6-ARYL-9-GLYCOSYLPURINES AND USE THEREOF | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2017-11-23 | — | — | US | disclosed |
| US-20170326168-A1 | 6-ARYL-9-GLYCOSYLPURINES AND USE THEREOF | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2017-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170326168-A1 | 6-ARYL-9-GLYCOSYLPURINES AND USE THEREOF | GART, DAO, GLA | ADORA1 309/4885ADORA3 553/4885ADORA2A 355/4885 |
| US-10550144-B2 | 6-aryl-9-glycosylpurines and use thereof | GART, DAO, GLA | ADORA1 309/4885ADORA3 553/4885ADORA2A 355/4885 |
| US-20170334943-A1 | 6-ARYL-9-GLYCOSYLPURINES AND USE THEREOF | UNG, FUT6, GART | ADORA1 328/4885ADORA3 387/4885ADORA2A 256/4885 |
| US-10100077-B2 | 6-aryl-9-glycosylpurines and use thereof | UNG, FUT6, GART | ADORA1 328/4885ADORA3 387/4885ADORA2A 256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.